MedTrace Logo

Outcomes for Patients With Gastro-Esophageal Reflux Disease

NCT03824548 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2019-01-31

No results posted yet for this study

Summary

Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide.

GERD poses substantial burden on both patients and society. EE treatment patterns and unmet needs have been well-studied overseas, but evidence gaps still exist in China.

To fill these evidence gaps, real-world evidence for GERD and EE are needed. To understand GERD market we will analysis :Patient profile,GERD patient journey within hospital (first present, get diagnosed, receive initial and maintenance treatment),medication cost,department differentiation.

To investigate current treatment patterns of GERD / EE in China we will analysis: Current agents used and treatment duration in clinical practice treatment patterns by different reimbursement status treatment pattern by EE/NERD.

To get healing rate of EE we will analysis: Real-world efficacy of the current standard treatment (i.e. PPIs) for patient with two test results of gastroscopy.

The data required for this project are accessible in hospital electronic system; no specific data collection tools or methods are required for this project design. Only algorithms for retrieving and extracting eligible patients' records are required and will be developed by HLT based on the eligibility criteria defined in this protocol.

Conditions

  • Gastro-esophageal Reflux Disease

Interventions

OTHER

this is non-intervention study, there is no intervention drug or device in this study.

this is exactly a non-interventional study, no intervention during the whole study.

Sponsors & Collaborators

  • Tianjin Happy Life Technology Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824548 on ClinicalTrials.gov